Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Vaccine Immunol. 2012 Apr;19(4):551-6. doi: 10.1128/CVI.05438-11. Epub 2012 Feb 15.

Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.

Author information

1
Center for Biologics Evaluation and Research, Food and Drug Administration, Washington, DC, USA. Lucia.Lee@fda.hhs.gov

Abstract

New multivalent CRM(197)-based conjugate vaccines are available for childhood immunization. Clinical studies were reviewed to assess meningococcal group C (MenC) antibody responses following MenC-CRM(197) coadministration with CRM(197)-based pneumococcal or Haemophilus influenzae type b conjugate vaccines. Infants receiving a total CRM(197) carrier protein dose of ∼50 μg and concomitant diphtheria-tetanus-acellular pertussis (DTaP)-containing vaccine tended to have lower MenC geometric mean antibody titers and continued to have low titers after the toddler dose. Nevertheless, at least 95% of children in the reported studies achieved a MenC serum bactericidal antibody (SBA) titer of ≥ 1:8 after the last infant or toddler dose. SBA was measured using an assay with a baby rabbit or human complement source. Additional studies are needed to assess long-term antibody persistence and MenC CRM(197) conjugate vaccine immunogenicity using alternative dosing schedules.

PMID:
22336285
PMCID:
PMC3318289
DOI:
10.1128/CVI.05438-11
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center